<![CDATA[Brii Biosciences and Vir Biotechnology, Inc. and VBI Vaccines Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=37534>Sat, 02 May 2026 00:56:39 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B]]>https://www.newswire.co.kr/newsRead.php?no=922107Fri, 23 Apr 2021 10:00:00 +0900<![CDATA[브리 바이오·비르 바이오테크·VBI 백신, B형 간염 치료 위해 BRII-179(VBI-2601) 및 BRII-835(VIR-2218)을 결합한 형태로 2상 임상 시험 개시]]>https://www.newswire.co.kr/newsRead.php?no=922108Fri, 23 Apr 2021 10:00:00 +0900